More About Colin
Colin Rom is the public policy lead for Bio + Health, building a16z into a leading voice of health innovation in Washington, D.C.
Prior to joining Andreessen Horowitz, Colin was the Managing Director of Science and Innovation Policy at Mayo Clinic, leading federal engagement strategy for policies focused on artificial intelligence, emerging biotechnology, and next generation care delivery. Before Mayo, Colin spent two years as a policy advisor in the Commissioner’s Office at the U.S. Food and Drug Administration, first as a policy advisor leading several agency-wide initiatives, and subsequently as the Senior Advisor to the Commissioner of Food and Drugs, while serving as a liaison between the FDA and White House Coronavirus Task Force and was a member of Operation Warp Speed. He also spent time as a policy and political advisor to the Director of Health Programs at the White House Office of Management and Budget and several years as a health policy advisor in the United States Senate, working for Senator Richard Burr (N.C.) and the Senate Committee on Health, Education, Labor, and Pensions.
Latest Content
-
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
-
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
-
The world is amidst an AI-driven industrial revolution. Whether we let it improve the health of Americans is up to how we regulate it. There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare.
